For adult patients with newly diagnosed acute myeloid leukemia (AML) who have been prescribed DAURISMO

PATIENT DOSING TRACKER

DAURISMO glasdegib tablets 100 mg | 25 mg

Not actual patients.

INDICATION

DAURISMO is a prescription medicine that is used with the medicine cytarabine to treat newly diagnosed acute myeloid leukemia (AML) in adults who:

- are 75 years of age or older, or
- have other medical conditions that prevent the use of standard chemotherapy

It is not known if DAURISMO is safe and effective in children.

SELECTED SAFETY INFORMATION

WARNING: DAURISMO can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects. For females who can become pregnant: Talk to your healthcare provider about the risks of DAURISMO to your unborn child. Your healthcare provider will do a pregnancy test within 7 days before you start taking DAURISMO. Do not use DAURISMO during pregnancy. Use effective birth control during treatment and for at least 30 days after your last dose of DAURISMO. Talk with your healthcare provider about what birth control method is right for you during this time. Talk to your healthcare provider right away if you have unprotected sex or if you think that your birth control has failed. Tell your healthcare provider right away if you become pregnant or think that you may be pregnant.

Please see Important Safety Information on pages 3 and 4 and click <u>here</u> for full Prescribing Information, including BOXED WARNING and Medication Guide.



PATIENT DOSING TRACKER

DAURISMO is taken with Low-Dose Cytarabine, a type of chemotherapy. See below for details on when and how to take DAURISMO and cytarabine.

		Adm	Administration			Schedule (28-day cycle)		
DAURISMO (100 m	ıg)	1 tab	1 tablet taken orally		Once daily			
Low-Dose Cytarab	ytarabine (20 mg)		Subcutaneous injection		Twice daily for Days 1-10 of ea			
se this checklist to Refer to the "How s instructions on how	Chea Chea If yo 2 do Rem heal should I tak	ck off your u miss a do ses of DAU ember to r thcare tean e DAURISMO.	daily doses ose of DAUF RISMO with efill your pr n's instructi O?" sectior	RISMO, take nin 12 hours rescriptions ons. n of the Med	on time an dication Gui	as you rem d always fo de in this d	ember. Do Ilow your ocument fo	
	IRISMO (once) JRISMO start		-		ng) Low	-		
DAURISMO	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	
Low-Dose Cytarabine	AM PM	AM PM	AM PM	AM PM	AM PM	AM PM	AM PM	
	DAY 8	DAY 9	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	
DAURISMO								
Low-Dose Cytarabine	AM PM	AM PM	AM PM					
DAURISMO	DAY 15	DAY 16	DAY 17	DAY 18	DAY 19	DAY 20	DAY 21	
DAORISHO	DAY 22	DAY 23	DAY 24	DAY 25	DAY 26	DAY 27	DAY 28	
DAURISMO	DAT 22	DAT 23	DAT 24	DAT 23	DAT 20	DAT 27	DAT 20	
CYCLE 2 Your DAURISMO start dat		date this cyc	:le:		_ Your DAUR	ISMO dose: _	·	
	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7	
DAURISMO								
Low-Dose	AM PM	AM PM	AM PM	AM PM	AM PM	AM PM	AM PM	
Low-Dose Cytarabine	AM PM DAY 8	AM PM DAY 9	AM PM	AM PM	AM PM	AM PM DAY 13	AM PM DAY 14	
Low-Dose Cytarabine DAURISMO	DAY 8	DAY 9	DAY 10					
Low-Dose Cytarabine DAURISMO	DAY 8	DAY 9 AM PM	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	
Low-Dose Cytarabine DAURISMO Low-Dose Cytarabine	DAY 8	DAY 9	DAY 10					
Low-Dose Cytarabine DAURISMO Low-Dose	DAY 8	DAY 9 AM PM	DAY 10	DAY 11	DAY 12	DAY 13	DAY 14	

Please see Important Safety Information on pages 3 and 4 and click <u>here</u> for full Prescribing Information, including BOXED WARNING and Medication Guide.



IMPORTANT SAFETY INFORMATION AND INDICATION

WARNING: DAURISMO can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects.

For females who can become pregnant: Talk to your healthcare provider about the risks of DAURISMO to your unborn child. Your healthcare provider will do a pregnancy test within 7 days before you start taking DAURISMO. Do not use DAURISMO during pregnancy. Use effective birth control during treatment and for at least 30 days after your last dose of DAURISMO. Talk with your healthcare provider about what birth control method is right for you during this time. Talk to your healthcare provider right away if you have unprotected sex or if you think that your birth control has failed. Tell your healthcare provider right away if you become pregnant or think that you may be pregnant.

For males: DAURISMO may affect fertility in males. Talk to your healthcare provider if this is a concern for you. It is not known if DAURISMO is present in semen. Do not donate semen during treatment with DAURISMO and for at least 30 days after your last dose. You should always use effective birth control, including a condom, even if you have had a vasectomy, during sex with female partners who are pregnant or who are able to become pregnant, during treatment with DAURISMO and for at least 30 days after your last dose to protect your female partner from being exposed to DAURISMO. Tell your healthcare provider right away if your partner becomes pregnant or thinks she is pregnant while you are taking DAURISMO.

Exposure to DAURISMO during pregnancy: If you think that you or your female partner may have been exposed to DAURISMO during pregnancy, talk to your healthcare provider right away. If you become pregnant during treatment with DAURISMO, you or your healthcare provider should report your pregnancy to Pfizer at 1-800-438-1985.

Blood donation: Do not donate blood or blood products during treatment with DAURISMO and for at least 30 days after the last dose.

QT prolongation: DAURISMO can cause serious side effects, including changes in the electrical activity of your heart called QT prolongation. This can cause irregular heartbeats that can be life-threatening. Tell your healthcare provider right away if you feel faint, light-headed, dizzy, or feel your heart beating irregularly or fast during treatment with DAURISMO.

(continued on next page)



IMPORTANT SAFETY INFORMATION AND INDICATION (continued)

Side effects: The most common side effects of DAURISMO with cytarabine include:

- Low red blood cell count (anemia)
- Tiredness
- Bleeding
- Fever with low white blood cell count
- Muscle pain
- Nausea
- Swelling of arms or legs

- Low platelet count
- Shortness of breath
- Decreased appetite
- Changes in taste
- Pain or sores in your mouth or throat
- Constipation
- Rash

These are not all of the possible side effects of DAURISMO. Call your doctor for medical advice about side effects. Your healthcare provider will perform certain tests to check for side effects before and during treatment with DAURISMO and may change your dose, temporarily stop, or permanently stop treatment with DAURISMO if you have certain side effects. Do not change your dose or stop taking DAURISMO unless your healthcare provider tells you.

Before you take DAURISMO: Tell your healthcare provider about all of your medical conditions. Tell them if you:

- Have heart problems including a condition called long QT syndrome
- Have abnormal blood salt (electrolytes) levels
- Are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.

Tell your healthcare provider about the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.

Breastfeeding: It is not known if DAURISMO passes into your breast milk. Do not breastfeed or provide breast milk to infants or children during treatment with DAURISMO and for at least 30 days after the last dose. Talk to your healthcare provider about the best way to feed your baby during this time.

INDICATION

DAURISMO is a prescription medicine that is used with the medicine cytarabine to treat newly diagnosed acute myeloid leukemia (AML) in adults who:

- are 75 years of age or older, or
- have other medical conditions that prevent the use of standard chemotherapy

It is not known if DAURISMO is safe and effective in children.



Not an actual patient.

Visit **Daurismo.com** to learn more.

For additional support, visit **PfizerOncologyTogether.com** or call **1-877-744-5675.**

SELECTED SAFETY INFORMATION

Exposure to DAURISMO during pregnancy: If you think that you or your female partner may have been exposed to DAURISMO during pregnancy, talk to your healthcare provider right away. If you become pregnant during treatment with DAURISMO, you or your healthcare provider should report your pregnancy to Pfizer at 1-800-438-1985.

Please see Important Safety Information on pages 3 and 4 and click <u>here</u> for full Prescribing Information, including BOXED WARNING and Medication Guide.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

October 2020

